MétaCan
Menu
Back to cohort
Record W3133335748 · doi:10.1097/ju.0000000000001561

Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study

2021· article· en· W3133335748 on OpenAlexaff
Avril Lusty, D. Robert Siemens, Mina Tohidi, Marlo Whitehead, Joan Tranmer, J. Curtis Nickel

Bibliographic record

VenueThe Journal of Urology · 2021
Typearticle
Languageen
FieldMedicine
TopicUrinary Bladder and Prostate Research
Canadian institutionsQueen's University
Fundersnot available
KeywordsMedicineHyperplasiaMedical therapyHeart failurePopulationUrologyInternal medicine

Abstract

fetched live from OpenAlex

Purpose: Increased risk of cardiac failure with a-blockers in hypertension studies and 5-alpha reductase inhibitors in prostate studies have raised safety concerns for long term management of benign prostatic hyperplasia.The objective of this study was to determine if these medications are associated with an increased risk of cardiac failure in routine care. Materials and Methods:This population based study used administrative databases including all men over 66 with a diagnosis of benign prostatic hyperplasia between 2005 and 2015.Men were categorized based on 5-alpha reductase inhibitor exposure and/or a-blocker exposure with a primary outcome of new cardiac failure utilizing competing risk models.Explanatory variables examined included exposure thresholds, formulations, age, and comorbidities associated with cardiac disease.Results: The data set included 175,201 men with a benign prostatic hyperplasia diagnosis with 8,339, 55,383, and 41,491 exposed to 5-alpha reductase inhibitor, a-blocker and combination therapy, respectively.Men treated with 5-alpha reductase inhibitor and a-blocker, alone or in combination, had a statistically increased risk of being diagnosed with cardiac failure compared to no medication use.Cardiac failure risk was highest for a-blockers alone (HR 1.22; 95% CI 1.18e1.26),intermediate for combination a-blockers/5-alpha reductase inhibitors (HR 1.16; 95% CI 1.12e1.21)and lowest for 5-alpha reductase inhibitors alone (HR 1.09; 95% CI 1.02e1.17).Nonselective a-blocker had a higher risk of cardiac failure than selective a-blockers (HR 1.08; 95% CI 1.00e1.17).Conclusions: In routine care, men with a benign prostatic hyperplasia diagnosis and exposed to both 5-alpha reductase inhibitor and a-blocker therapy had an increased association with cardiac failure, with the highest risk for men exposed to nonselective a-blockers.Key Words: prostatic hyperplasia, heart failure, 5-alpha reductase inhibitors, adrenergic alpha-antagonists, lower urinary tract symptoms BENIGN prostatic hyperplasia and cardiovascular diseases are common conditions in the aging male.1,2 Mounting evidence suggests that a relationship between the two may be due to more than chance alone, potentially with shared pathophysiological processes.3,4 Although still unclear, proposed underlying mechanisms of this association include cigarette smoking, high blood pressure, and dyslipidemia.Other suggested causal factors include oxidative stress, vascular calcification, and metabolic syndrome.5 Chronic inflammation may also play a pivotal role in this link between BPH and cardiac Abbreviations and Acronyms

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.308
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations47
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicUrinary Bladder and Prostate ResearchFrench-language works237,207